Sinopharm Tech Holdings Limited
國 藥 科 技 股 份 有 限 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

ANNOUNCEMENT IN RELATION TO PUBLIC FLOAT

The board of directors (the "**Board**") of Sinopharm Tech Holdings Limited (the "**Company**") hereby announces that, due to inadvertent oversight of the requirement of public float, as at the date of this announcement, the public float of the Company is approximately 24.95%, which is below the minimum public float of 25.0% prescribed under Rule 17.37B(1) of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the "**GEM Listing Rules**").

To the best of the knowledge, information and belief of the directors of the Company (the "**Directors**"), the shareholding structure of the Company as at the date of this announcement is set out below:

Shareholders	**Number of ordinary shares held**	**% of the total number of issued ordinary shares of the Company**
Integrated Asset Management (Asia) Limited	321,694,520	50.76
Quantum Worldwide Investments Limited	150,000,000	23.67
Heung Pik Lun *(Note)*	3,920,000	0.62
Public shareholders	158,078,535	24.95
Total	**633,693,055**	**100.00**

Note: Mr. Heung Pik Lun is an independent non-executive Director and therefore the ordinary shares held by him is not regarded as in public hands.

The Company is considering various options to restore the public float, including but not limited to procuring some of the above shareholders of the Company to sell its/his ordinary shares and/or issuing new ordinary shares to the public.

The Company expects to restore the public float of the Company within 3 months from the date of this announcement. The Company will make further announcements in due course in compliance with the GEM Listing Rules to provide the shareholders of the Company with further details regarding the efforts to restore the public float.

The Company regrets that the shortfall in public float arose due to inadvertent and unintentional oversight.

To strengthen its internal control procedures and avoid any occurrence of similar incidents in the future, the Company will implement the following measures with immediate effect:

(a) the Company will enhance its directors' securities dealing clearance procedures so that, in addition to the procedures adopted pursuant to Rules 5.48 to 5.67 of the GEM Listing Rules, the Company will perform a public float impact assessment before granting any dealing clearance to a director, and will not grant clearance for any dealing that may cause (or further worsen) a public float shortfall; and

(b) the Company will conduct periodic review(s) (at least monthly) of the Company's shareholding structure and public float position and will promptly escalate any potential public float issue to the Board for consideration and, where appropriate, timely disclosure and remedial action.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
KWOK Shuk Yi
Executive Director

Hong Kong, 16 September 2026

As at the date of this announcement, the Board comprises Mr. CHIU Sin Nang Kenny and Ms. KWOK Shuk Yi as executive Directors, and Mr. LAU Fai Lawrence, Mr. HEUNG Pik Lun, Mr. DIU Peter and Mr. YU Ping Ming as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the website of The Stock Exchange of Hong Kong Limited at https://www.hkexnews.hk for a minimum period of 7 days from the date of its publication and on the website of the Company at http://www.sinopharmtech.com.hk.